Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors and generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 26.62 kDa 
• Atom Count: 1900 
• Residue Count: 209 
• Unique protein chains: 1

4O05

Identification of novel HSP90/isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington's disease

• DOI: 10.2210/pdb4O05/pdb

• Classification: CHAPERONE/CHAPERONE INHIBITOR
• Organism(s): Homo sapiens
• Expression System: Spodoptera frugiperda
• Mutation(s): No 


• Deposited: 2013-12-13 Released: 2014-04-09 
• Deposition Author(s): Zuccola, H.J., Ernst, J.T.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 1.79 Å
• R-Value Free: 0.215 
• R-Value Work: 0.188 
• R-Value Observed: 0.189 

Literature

Identification of Novel HSP90 alpha / beta Isoform Selective Inhibitors Using Structure-Based Drug Design. Demonstration of Potential Utility in Treating CNS Disorders such as Huntington's Disease.

Ernst, J.T., Neubert, T., Liu, M., Sperry, S., Zuccola, H., Turnbull, A., Fleck, B., Kargo, W., Woody, L., Chiang, P., Tran, D., Chen, W., Snyder, P., Alcacio, T., Nezami, A., Reynolds, J., Alvi, K., Goulet, L., Stamos, D.

(2014) J Med Chem 57: 3382-3400

• PubMed: 24673104 
• DOI: 10.1021/jm500042s
• Structures With Same Primary Citation


• PubMed Abstract: 
  

A structure-based drug design strategy was used to optimize a novel benzolactam series of HSP90α/β inhibitors to achieve >1000-fold selectivity versus the HSP90 endoplasmic reticulum and mitochondrial isoforms (GRP94 and TRAP1, respectively). Selective HSP90α/β inhibitors were found to be equipotent to pan-HSP90 inhibitors in promoting the clearance of mutant huntingtin protein (mHtt) in vitro, however with less cellular toxicity. Improved tolerability profiles may enable the use of HSP90α/β selective inhibitors in treating chronic neurodegenerative indications such as Huntington's disease (HD). A potent, selective, orally available HSP90α/β inhibitor was identified (compound 31) that crosses the blood-brain barrier. Compound 31 demonstrated proof of concept by successfully reducing brain Htt levels following oral dosing in rats.

---

Organizational Affiliation: 

Vertex Pharmaceuticals , 11010 Torreyana Road, San Diego, California 92121, United States.

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
Heat shock protein HSP 90-alpha	A	233	Homo sapiens	Mutation(s): 0  Gene Names: HSP90AA1, HSP90A, HSPC1, HSPCA
Find proteins for P07900 (Homo sapiens) Explore P07900  Go to UniProtKB:  P07900
NIH Common Fund Data Resources
PHAROS  P07900 GTEx  ENSG00000080824

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
2Q9	A	2,7,7-trimethyl-9-[1-oxo-8-(propan-2-ylamino)-1,2,3,4-tetrahydroisoquinolin-6-yl]-1,2,3,4,6,7,8,9-octahydro-5H-beta-carbolin-5-one C26 H34 N4 O2 SAYWXJCRCITRBW-UHFFFAOYSA-N

External Ligand Annotations
ID	Binding Affinity (Sequence Identity %)
2Q9	IC50:  73   nM  BindingDB
2Q9	Ki:  37   nM  BindingDB
2Q9	Ki:  37   nM  Binding MOAD
2Q9	Ki:  30   nM  BindingDB

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 1.79 Å
• R-Value Free: 0.215 
• R-Value Work: 0.188 
• R-Value Observed: 0.189 
• Space Group: I 2 2 2

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 69.28	α = 90
b = 89.49	β = 90
c = 97.93	γ = 90

Software Package:

Software Name	Purpose
BUSTER-TNT	refinement
PDB_EXTRACT	data extraction
PROCESS	data collection
PROCESS	data reduction
PROCESS	data scaling
BUSTER	refinement

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2013-12-13 
• Released Date: 2014-04-09 
Deposition Author(s): Zuccola, H.J., Ernst, J.T.

Revision History 

• Version 1.0: 2014-04-09
  Type: Initial release
  
• Version 1.1: 2014-05-07
  Changes: Database references
• Version 1.2: 2017-11-22
  Changes: Refinement description